About cnetsadmin

This author has not yet filled in any details.
So far cnetsadmin has created 60 blog entries.

Temozolomide Access in Ontario

CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]

By |2021-07-07T21:48:16+00:00July 6th, 2021|Treatment News|Comments Off on Temozolomide Access in Ontario

Lutathera Funded in Saskatchewan

As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]

By |2021-07-06T18:30:28+00:00July 6th, 2021|Treatment News|Comments Off on Lutathera Funded in Saskatchewan

LUTATHERA Funded In British Columbia

CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide [...]

By |2021-05-30T15:16:40+00:00March 8th, 2021|Treatment News|Comments Off on LUTATHERA Funded In British Columbia

INSPIRATIONAL NET CANCER PATIENT STORY

INSPIRATIONAL NEUROENDOCRINE CANCER PATIENT STORY Long-time CNETS fundraisers Bryde Fresque and Natalie Mezey, share a message of hope! As outlined in this Ottawa Hospital Foundation report, Bryde Fresque [...]

By |2021-05-30T15:17:55+00:00February 11th, 2021|News|Comments Off on INSPIRATIONAL NET CANCER PATIENT STORY

ESMO Guidelines: Lung & Thymic Carcinoids

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Published January 19, 2021 Highlights This updated ESMO Clinical Practice Guideline [...]

By |2021-05-30T15:18:56+00:00February 4th, 2021|Publication|Comments Off on ESMO Guidelines: Lung & Thymic Carcinoids

European Journal of Cancer Article

Article: Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era February 2021 - European Journal of Cancer, Review [...]

By |2021-05-30T15:19:56+00:00January 5th, 2021|Research|Comments Off on European Journal of Cancer Article

INCA NETInfo

INCA GLOBAL NET PATIENT INFO PACK NEW FOR 2020! - NETInfo INCA launches a range of factsheets on NETs that are free to download. These factsheets provide [...]

By |2020-12-26T03:59:28+00:00December 26th, 2020|Education|Comments Off on INCA NETInfo

LUTATHERA® Funded in Ontario

Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs [...]

By |2020-10-10T14:14:05+00:00October 10th, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Ontario

LUTATHERA® Funded in Quebec

As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients [...]

By |2020-10-03T15:46:51+00:00October 3rd, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Quebec
Go to Top